Tina Nielsen

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 424 citations

Medicine, Hematology, Oncology +12

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

Jean-Pascal Machiels, Somasundaram Subramanian, Ágnes Ruzsa et al. · The Lancet Oncology · 2011 · 242 citations

Medicine, Oncology, Pharmacotherapy +12

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales et al. · Journal of Clinical Oncology · 2018 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Bertrand Coiffier, Barbara Pro, H. Miles Prince et al. · Journal of Hematology & Oncology · 2014 · 209 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher et al. · Blood · 2022 · 163 citations · Full text

Medicine, Oncology, Survival Analysis +12